Skip to Content

Genmab A/S GMAB

Morningstar Rating
DKK 1,824.00 −23.00 (1.25%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Genmab Earnings: Robust Darzalex Royalty Revenue Supports Future Growth; Shares Undervalued

Narrow-moat Genmab reported robust first-quarter results highlighted by revenue of DKK 4.1 billion, a 46% increase from the prior-year period. Royalty revenue from Darzalex continued to drive sales, accounting for 57% of total revenue in the quarter. Genmab’s results are tracking our expectations, and we maintain our fair value estimate of DKK 2,650 per share. We view the stock as undervalued, currently trading in 4-star territory at about 27% below our fair value estimate.

Price vs Fair Value

GMAB is trading at a 214% premium.
Price
DKK 1,847.00
Fair Value
DKK 4,726.00
Uncertainty
Medium
1-Star Price
DKK 7,689.20
5-Star Price
DKK 1,684.00
Economic Moat
Mywdvk
Capital Allocation
Xmvsxsqy

Bulls Say, Bears Say

Bulls

Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.

Bears

The multiple myeloma market is crowded with other molecules, including immunomodulatory drugs, proteasome inhibitors, HDAC inhibitors, and other targeted therapies.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GMAB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
DKK 1,847.00
Day Range
DKK 1,823.001,851.00
52-Week Range
DKK 1,814.002,814.00
Bid/Ask
DKK 1,828.00 / DKK 1,828.50
Market Cap
DKK 117.16 Bil
Volume/Avg
165,225 / 135,365

Key Statistics

Price/Earnings (Normalized)
22.27
Price/Sales
7.02
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.47%

Company Profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
2,266

Competitors

Valuation

Metric
GMAB
4502
INCY
Price/Earnings (Normalized)
22.2715.6815.68
Price/Book Value
3.800.892.48
Price/Sales
7.021.533.57
Price/Cash Flow
18.587.5017.18
Price/Earnings
GMAB
4502
INCY

Financial Strength

Metric
GMAB
4502
INCY
Quick Ratio
12.420.463.29
Current Ratio
12.461.063.47
Interest Coverage
216.181.93333.13
Quick Ratio
GMAB
4502
INCY

Profitability

Metric
GMAB
4502
INCY
Return on Assets (Normalized)
15.15%2.86%13.25%
Return on Equity (Normalized)
16.99%6.13%17.32%
Return on Invested Capital (Normalized)
14.01%4.78%14.51%
Return on Assets
GMAB
4502
INCY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
HkkcvhpbRfdhjc$124.3 Bil
Regeneron Pharmaceuticals Inc
REGN
CzfzzgpzLvbcnv$111.3 Bil
Moderna Inc
MRNA
CwgcwyqpRtht$56.9 Bil
BioNTech SE ADR
BNTX
JhbstrqsNcvyj$24.2 Bil
argenx SE ADR
ARGX
VylmxbqkJdmy$22.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
RvbwphchGydws$20.1 Bil
Biomarin Pharmaceutical Inc
BMRN
HxbwnrdgKhrkm$16.1 Bil
Incyte Corp
INCY
KmcnyqxQrpfxnv$13.4 Bil
Royalty Pharma PLC Class A
RPRX
ZntpmvsbwMgxjzj$12.4 Bil
United Therapeutics Corp
UTHR
FlzchvsBrcvt$12.2 Bil

Sponsor Center